News Sentiment

190A sentiment intelligence

CHORDIA THERAPEUTICS INC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report RSS feed
Weighted score 50 Balanced news tone 1 relevant articles
Exchange JPX Japan
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 82.00 Week of 10 Jul 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Earnings

72/100 classification confidence.

Company focus 1

directly relevant article

Source quality 0

high-authority source matches

Trend context Trend inactive

+2.5% over one week, -15.5% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

[Q&A session at end] Chordia Therapeutics to report interim U.S. trial results for rogocekib in mid-2026, targeting marketing approval filing by end of 2028

Market Reaction

Balanced read

55/100 confidence

News tone and price action are not far from neutral.

Primary event Earnings 72/100 classification
One-week reaction 2.5% Price confirming higher
Trend fit Trend inactive -15.5% over four weeks
Fair value -63.9% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 0
Neutral 1
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 1
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
ログミーFinance 1

Event Lens

What the news is about

Classified themes
Earnings 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-1 of 1